New York Life Investment Management LLC Boosts Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

New York Life Investment Management LLC increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 6.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,384 shares of the biopharmaceutical company’s stock after buying an additional 153 shares during the period. New York Life Investment Management LLC’s holdings in Alnylam Pharmaceuticals were worth $561,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. Allegiance Financial Group Advisory Services LLC purchased a new position in Alnylam Pharmaceuticals in the 4th quarter worth about $228,000. Nwam LLC increased its stake in Alnylam Pharmaceuticals by 5.8% in the 4th quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company’s stock worth $213,000 after buying an additional 50 shares during the period. Illinois Municipal Retirement Fund increased its stake in Alnylam Pharmaceuticals by 67.7% in the 4th quarter. Illinois Municipal Retirement Fund now owns 62,665 shares of the biopharmaceutical company’s stock worth $14,746,000 after buying an additional 25,298 shares during the period. Amalgamated Bank increased its stake in Alnylam Pharmaceuticals by 2.5% in the 4th quarter. Amalgamated Bank now owns 8,484 shares of the biopharmaceutical company’s stock worth $1,996,000 after buying an additional 205 shares during the period. Finally, IFP Advisors Inc increased its stake in Alnylam Pharmaceuticals by 24.2% in the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 47 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 0.2 %

ALNY stock opened at $242.93 on Wednesday. The firm has a 50 day moving average of $254.35 and a 200 day moving average of $262.08. The stock has a market capitalization of $31.45 billion, a PE ratio of -111.95 and a beta of 0.35. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analyst Weigh In

ALNY has been the topic of a number of research reports. Royal Bank of Canada reissued an “outperform” rating and set a $310.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th. Canaccord Genuity Group raised their target price on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a “buy” rating in a research report on Tuesday, February 18th. Wolfe Research downgraded shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday, November 12th. Finally, HC Wainwright raised their target price on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a research report on Monday, February 24th. One analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $304.26.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,548 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total transaction of $389,585.16. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares of the company’s stock, valued at approximately $3,017,271.63. This trade represents a 11.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40. Following the transaction, the executive vice president now directly owns 12,881 shares of the company’s stock, valued at $3,240,344.36. This represents a 10.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 72,986 shares of company stock valued at $20,397,849. 1.50% of the stock is owned by insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.